Treatment for Alcohol-Related Liver Injury with Jaundice and Coagulopathy
For patients with alcohol-related liver injury presenting with jaundice and coagulopathy, immediately assess disease severity using Maddrey Discriminant Function (mDF) or MELD score, screen for infections, and if mDF ≥32 or MELD >20 without contraindications, initiate prednisolone 40 mg daily for 28 days while ensuring nutritional intake of at least 35-40 kcal/kg body weight. 1, 2
Initial Assessment and Risk Stratification
Calculate Disease Severity
- Use mDF ≥32 or MELD >20 to define severe disease requiring pharmacologic intervention 1, 2
- Alternatively, Glasgow Alcoholic Hepatitis Score (GAHS) ≥9 can be used 2
- These thresholds identify patients with 30-50% one-month mortality risk who benefit from treatment 3
Mandatory Screening Before Treatment
Before initiating any therapy, you must systematically exclude:
- Active infections (chest x-ray, blood cultures, urine cultures, ascitic fluid cultures if ascites present) 1, 2
- Acute kidney injury with creatinine >2.5 mg/dL 1
- Active gastrointestinal bleeding 1
- Other liver diseases: hepatitis B/C, drug-induced liver injury, hepatocellular carcinoma, acute pancreatitis 1
- Obtain abdominal ultrasound to exclude biliary obstruction 1
Treatment Algorithm for Severe Disease (mDF ≥32 or MELD >20)
Corticosteroid Therapy
Prednisolone 40 mg daily (or methylprednisolone 32 mg daily) for 28 days is the only proven pharmacologic therapy, providing short-term survival benefit with 1-month mortality improving from 35% to 20% in treated patients 2, 3. The STOPAH trial demonstrated borderline mortality reduction at 28 days, though no benefit beyond one month 2.
Critical caveat: Corticosteroids only benefit approximately 50-60% of patients and carry infection/bleeding risks 2, 4. This is why response assessment is mandatory.
Adjunctive N-Acetylcysteine
Consider adding intravenous N-acetylcysteine for 5 days in combination with corticosteroids 2. While evidence is not definitive, guidelines suggest this combination may provide additional benefit in severe cases 2.
Assess Treatment Response at Day 7
Calculate the Lille score at day 7 to identify non-responders 1, 2:
- Lille <0.45: Continue prednisolone for full 28 days 1, 2
- Lille ≥0.45: Stop corticosteroids immediately, particularly if ≥0.56 (null responders) 2
This stopping rule is critical because continued corticosteroid exposure in non-responders only increases infection risk without survival benefit 2.
Nutritional Management (All Patients)
Target 35-40 kcal/kg body weight daily with 1.2-1.5 g/kg protein intake 2. This is non-negotiable—a post-hoc analysis demonstrated that patients achieving <21.5 kcal/kg had significantly higher mortality and infection rates regardless of other treatments 2.
Route of Nutrition
- Prefer oral route first-line 2
- Use nasogastric tube feeding if oral intake inadequate, despite tolerance issues 2
- Supplement with B-complex vitamins 2
- Avoid parenteral nutrition due to line sepsis risk unless no other option 2
Management of Coagulopathy
The coagulopathy in alcohol-associated hepatitis reflects synthetic liver dysfunction. Do not routinely correct coagulopathy with FFP or vitamin K unless active bleeding or invasive procedures are planned. The INR/PT serves as a prognostic marker (included in mDF and MELD calculations) rather than a treatment target 1.
Infection Surveillance and Management
Perform systematic infection screening before, during, and after corticosteroid therapy 2. This is critical because:
- Infection is a contraindication to starting corticosteroids 1
- Patients on corticosteroids have heightened infection risk 2
- One study showed continued antibiotics during prednisolone reduced 90-day mortality from 52% to 13% in infected patients 2
Specific Infection Concerns
- Screen for invasive aspergillosis in ICU patients or MELD ≥24 (serum galactomannan ≥0.5) 2
- Consider pneumocystis pneumonia screening in corticosteroid-treated patients 2
- Treat infections aggressively before considering corticosteroids 2
Supportive Care Measures
Avoid Nephrotoxins
- No IV contrast, aminoglycosides, or NSAIDs 1
- Cautious diuretic use 1
- Early albumin and vasoconstors if hepatorenal syndrome develops 1
Manage Alcohol Withdrawal
Address alcohol withdrawal syndrome concurrently with liver-directed therapy 5, 4
Multidisciplinary Involvement
For patients with SIRS, multi-organ failure, or ICU-level care needs, involve hepatology, critical care, infectious disease, and nephrology specialists 1
Treatment for Non-Severe Disease (mDF <32 and GAHS <9)
No specific pharmacologic therapy is indicated 2. Focus on:
- Nutritional support (same targets as severe disease)
- Alcohol abstinence counseling and treatment
- Vitamin supplementation
- Monitoring for disease progression
Liver Transplantation Consideration
For non-responders to corticosteroids (Lille ≥0.45), evaluate for early liver transplantation in highly selected patients 2. This represents a paradigm shift, as early transplantation for alcohol-associated hepatitis is increasingly accepted in carefully selected cases with low relapse risk 3, 4.
For decompensated cirrhosis, consider transplantation if MELD remains >17 after 3 months of abstinence 3.
Long-Term Management
Lifelong alcohol abstinence is the single most important determinant of long-term survival, with 10-year survival of 88% in abstinent patients versus 73% in those who relapse 3. Integrate addiction medicine specialists and social workers into care 4.
Common Pitfalls to Avoid
- Starting corticosteroids without infection screening—this increases mortality
- Continuing corticosteroids beyond day 7 in non-responders—exposes patients to infection risk without benefit
- Inadequate nutritional support—independently predicts mortality
- Treating mild disease (mDF <32) with corticosteroids—no proven benefit, only risks
- Correcting coagulopathy routinely—wastes resources and doesn't improve outcomes unless bleeding